The Next Healthcare Cost Shock Is Coming for U.S. Employers

For U.S. employers, healthcare is becoming a more difficult cost to budget for. Employer healthcare costs are projected to rise 9.5% in 2027, pushing average spending above $19,000 per employee, according to insurance broker Aon. The increase would mark a fourth consecutive year of near-double-digit growth and extend a period of unusually persistent pressure on employer-sponsored health plans.

The significance goes beyond benefits departments. Health insurance is a major component of total compensation, meaning sustained increases can influence wage decisions, hiring, retention, corporate margins and household finances. Employers ultimately have several ways to absorb higher costs, but each involves a trade-off: pay more themselves, shift more costs to employees, redesign benefits or attempt to reduce the underlying use and price of healthcare.

A cost problem that has become persistent

The latest increase is notable because it is not simply another consequence of broad inflation. Aon says employer healthcare costs rose from 3.7% in 2022 to 8.8% in 2026. The company attributes the latest pressure principally to greater use of medical services, the prevalence of chronic conditions, high-cost claims and increased spending on specialty medicines.

That distinction matters. If healthcare costs were rising primarily because of general inflation, an easing in economy-wide price pressures could eventually provide relief. But utilization and the composition of care can continue to push spending higher even when headline inflation moderates.

The underlying system is also large. Employer-sponsored insurance covers roughly 154 million people under 65, making businesses one of the most important channels through which Americans receive health coverage. In 2025, average annual premiums reached $9,325 for individual coverage and $26,993 for family coverage, according to KFF. Family premiums rose 6% that year.

What is driving the increase?

Prescription drugs are one of the clearest pressure points. Employers are contending with rising use of specialty medicines, costly new therapies and growing demand for GLP-1 medications used to treat diabetes and, increasingly, obesity.

The issue is particularly complicated because these medicines sit at the intersection of cost and potential long-term health benefits. An employer paying for an expensive treatment today may hope to avoid more costly complications later, but those savings can be difficult to measure and may not accrue within the same time period or even to the same insurer.

Recent employer surveys illustrate the tension. Business Group on Health found that 67% of surveyed employers currently cover GLP-1 medicines for weight management, but among those employers, only 72% said they were likely to continue that coverage in 2027.

Employers are therefore moving toward tighter eligibility requirements, utilization management and closer scrutiny of pharmacy-benefit arrangements rather than treating drug coverage as a static benefit.

Medical care itself is another major driver. Aon points to increased utilization, chronic conditions and a growing number of high-cost claims. Cancer remains a particularly significant source of employer spending, while musculoskeletal and cardiovascular conditions also contribute materially to costs.

The bill does not stay with employers

Companies have historically absorbed a substantial share of health insurance costs. But when expenses rise faster than budgets, the financial burden can move through several channels.

One is employee cost-sharing. Mercer reported in June that 48% of large U.S. employers expected to make changes to their medical plans for 2027 that could increase employees' out-of-pocket costs, including higher deductibles or copayments.

This creates a delicate compensation equation. An employer may limit the increase in its own healthcare spending by increasing payroll deductions or deductibles, but employees experience the change as a reduction in the value of their compensation.

That effect is especially important for lower-paid workers and families with significant medical needs. KFF found that workers with employer-sponsored family coverage contributed an average of $6,850 toward premiums in 2025, while employees at smaller firms generally paid a larger share of family premiums than those at larger companies.

For businesses, the alternative is to absorb more of the increase. That protects employees but puts additional pressure on operating costs. In industries with narrow margins, employers may have less room to do so than large companies with greater pricing power or financial flexibility.

Companies are changing the way they manage benefits

The emerging response is not simply to cut benefits. Employers are experimenting with different mechanisms for controlling the cost of care while attempting to preserve access.

Mercer found that nearly one-third of large employers either offer or plan to offer non-traditional medical plans for 2027, including arrangements that steer employees toward selected high-performing providers. Another 38% were considering such approaches.

Pharmacy benefits are also under review. Employers are examining contracts with pharmacy-benefit managers, utilization controls and alternative arrangements intended to provide greater visibility into costs.

The economic logic is straightforward: if employers cannot substantially change the demand for healthcare, they can try to influence where employees receive care, which treatments are covered, how providers are paid and how much employees pay at the point of service.

But these strategies have limits. Steering workers toward lower-cost providers may reduce spending, for example, while poorly designed restrictions could create access problems or discourage necessary treatment. Cost containment therefore involves more than finding the cheapest option; employers must also consider outcomes and employee experience.

What happens next?

The 9.5% projection is a forecast, not a predetermined outcome. Actual spending could differ depending on medical utilization, pharmaceutical pricing, insurance negotiations, provider prices, new treatments and changes in plan design.

For employers, however, the immediate challenge is less about predicting the exact number than preparing for continued uncertainty. Several years of elevated cost growth make healthcare increasingly relevant to broader corporate planning.

For workers, the direction of travel could mean more varied benefit designs and greater responsibility for choosing providers, medications and insurance plans. For investors, sustained benefit inflation can become another component of labor costs and therefore a factor in assessing margins, particularly in labor-intensive businesses.

Governments and policymakers face a different problem. Employer-sponsored insurance remains central to the U.S. healthcare system, so persistent cost increases can eventually affect public debates over drug pricing, healthcare delivery, insurance regulation and affordability.

The deeper issue is that healthcare costs are no longer behaving like a temporary corporate expense that can be budgeted around for a year or two. They are becoming a structural consideration in the economics of employing people.

If medical utilization, high-cost treatments and pharmaceutical spending continue to rise, employers will have to decide how much of the burden they can absorb and how much they can reasonably transfer. The choices made in the next few benefit cycles will help determine not only what companies spend on healthcare, but also how workers experience the value of employment itself.